However, payer policies appear to support AstraZeneca’s Symbicort & Merck’s Dulera over the GSK combinations, according to Spherix Global Insights, GmbH September 24, 2015 – Zug, Switzerland – The recent release of RealTime Dynamix: Asthma and COPD suggests that prescribing…
TNF share expected to erode as Otezla sees greater adoption, according to Spherix Global Insights, GmbH September 8, 2015 – Zug, Switzerland – Feedback gathered from 101 US rheumatologists during late July and early August reveals a major shift in…
Over 40% of current Xeljanz users expect to increase use, with many rheumatologists initiating the agent prior to biologics, according to Spherix Global Insights, GmbH September 1, 2015 – Zug, Switzerland – Feedback gathered from 101 rheumatologists in August reveals…
Familiarity with Auryxia is the primary barrier to adoption and growth, according to Spherix Global Insights, GmbH August 20, 2015 – Zug, Switzerland –RealTime Dynamix: Nephrology reveals that while Keryx contact rates for Auryxia are in line with those of…
According to business intelligence firm, Spherix Global Insights, GmbH while platform injectables will maintain a majority patient share for MS in the short term, erosion will continue as neurologists seek to arrest disease progression sooner with more aggressive treatment. …
Spherix Global Insights, GmbH introduces RealTime Dynamix, a new rapid turnaround service for industry monitoring and insights August 13, 2015 – Zug, Switzerland – Spherix Global Insights announces the launch of RealTime Dynamix, its new monthly service developed to keep…